
Acquisition - April 21, 2015
Novo Nordisk, Janssen Sign Pact
Novo Nordisk A/S and Janssen Biotech, Inc. have signed an agreement that will allow Janssen to acquire an exclusive global license to further develop and commercialize a clinical program focused on therapy within autoimmune diseases. The program targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor), according to Novo Nordisk. The […]